Skip to Content
You are currently on the new version of our website. Access the old version .
CancersCancers
  • Editorial
  • Open Access

25 June 2023

3 Pages

HER-2-Positive Tumors: A Continuously Evolving Field in Cancer Research

,
and
1
Mannheim Cancer Center, University Hospital Mannheim, University of Heidelberg, 68167 Mannheim, Germany
2
Klinik und Poliklinik für Innere Medizin III, Technische Universität München, 81675 München, Germany
3
Zentrum für Geburtshilfe und Gynäkologie, St. Elisabethen Krankenhaus Lörrach, 79539 Lörrach, Germany
*
Author to whom correspondence should be addressed.

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

Almost 25 years ago, trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), was licensed for the treatment of patients with metastatic HER2-positive breast cancer in the United States of America (USA) [...]

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.